Phaseline

Companies › Shanghai Synvida Biotechnology

Shanghai Synvida Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Respiratory, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SV001–Phase 2Idiopathic Pulmonary Fibrosis(IPF)Dec 2026
SV003–Phase 1Healthy ParticipantsMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07121413SV001Phase 2Idiopathic Pulmonary Fibrosis(IPF)RespiratoryDec 2026
NCT07469085SV003Phase 1Healthy ParticipantsOtherMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Kymera Therapeutics Tortugas Neuroscience Shanghai Yidian Pharmaceutical Technology Development ReAlta Life Sciences Insmed

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.